SYNIMMUNE Competitors and Similar CompaniesClear all
SYNIMMUNE's competitors and similar companies include Ascendis Pharma and Allogene Therapeutics.
 SYNIMMUNE SYNIMMUNE is a biotechnology company dedicated to the development of mono- and bispecific anti-tumor antibodies. |  Ascendis Pharma Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology. |  Allogene Therapeutics Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. | |
Founding Date | Founding Date 2010 | Founding Date 2007 | Founding Date 2018 |
Type | Type Private | Type Public | Type Public |
Tags | |||
Locations | Locations Tübingen, DE HQ | Locations Hellerup, DK HQ Heidelberg, DE Palo Alto, US | Locations South San Francisco, US HQ |
Employees | Employees 5 | Employees 1,017 | Employees 2263% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 7.7 b | Valuation ($) 585.5 m |
Financial | |||
Net income | Net income N/A | Net income (€228m) (FY, 2025) | Net income ($190.9m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 85.8m | Total funding raised $ 532m |
For sources of this data, please see the company profile
View Company Profiles
Ascendis Pharma
HQ
Hellerup, DK
Employees
1,017
Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology.
View companyAllogene Therapeutics
HQ
South San Francisco, US
Employees
226↓ 3% decrease
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
View company